中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

20 records (took 0.013 seconds)

    PROTEASE-ACTIVATING CD45-GATE CAR
    12.
    发明申请
    PROTEASE-ACTIVATING CD45-GATE CAR 有权

    公开(公告)号：US20220227832A1

    公开(公告)日：2022-07-21

    申请号：US17557654

    申请日：2021-12-21

    Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

    Inventor： Shanshan LANG ,  Thomas John VAN BLARCOM ,  Michael Thomas BETHUNE ,  Siler PANOWSKI ,  Nguyen TAN ,  Yi ZHANG ,  Barbra Johnson SASU ,  Zhe LI

    IPC: C07K14/725 ,  C07K14/705 ,  C12N15/79 ,  C07K19/00

    Abstract: A reversibly gated effector polypeptide e.g. a chimeric antigen receptor (protease-activating CD45-gate CAR) comprising an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. Nucleic acids including vectors and expression vectors that encode the protease-activating CD45-gate CAR and cells including immune cells such as T cells that comprise and express the nucleic acids. Methods of treatment of various conditions including various forms of cancer comprising administering the cells including CAR T cell therapy. In some embodiments, the CD45 gate at least partially inhibits activation of the protease-activating CD45-gate CAR when the protease-activating CD45-gate CAR binds antigen. The inhibition is at least partially diminished, relieved and/or eliminated when the protease-activating CD45-gate CAR is exposed to a protease that can cleave the linker.

    BCMA CAR-T CELLS WITH ENHANCED ACTIVITIES
    13.
    发明申请
    BCMA CAR-T CELLS WITH ENHANCED ACTIVITIES 有权

    公开(公告)号：US20210260118A1

    公开(公告)日：2021-08-26

    申请号：US17183689

    申请日：2021-02-24

    Applicant: Allogene Therapeutics, Inc.

    Inventor： Regina Junhui LIN ,  Siler PANOWSKI ,  Cesar Adolfo SOMMER ,  Thomas John VAN BLARCOM ,  Barbra Johnson SASU ,  Arun BALAKUMARAN

    IPC: A61K35/17 ,  C07K14/715 ,  C07K16/28 ,  C12N15/86 ,  A61P35/00

    Abstract: Provided here are engineered immune cells that comprise a constitutively active chimeric cytokine receptor (CACCR) and a B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR). Also provided herein are engineered immune cells that comprise one or more nucleic acids e.g. a bicistronic vector such as a viral vector that encode the CACCRs and BCMA CARs and engineered immune cells e.g. engineered autologous or allogeneic T cells that express both CACCRs and BCMA CARs from the nucleic acids. When present on chimeric antigen receptor (CAR)-bearing engineered immune cells, the CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Further provided herein are methods of making and using the engineered immune cells described herein, such as methods of treating a disease or condition by administering at least one appropriate dose of the cells to a patient suffering from the condition.

Patent Agency Ranking